Evaluating treatment efficacy of citalopram, symbiotic, and mebeverine for children with functional abdominal pain.

Phase 2

Active, not recruiting

• Conditions: Children's functional abdominal pain; Children mental health; Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon; Mental Health - Other mental health disorders

• Registration Number: ACTRN12613000158763
• Lead Sponsor: Isfahan University of medical silences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-02-11
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Children between 6 to 18 years old, having functional abdominal pain according to ROME III criteria, having not consumption of probiotics and antibiotics in previous 2 months

Exclusion Criteria

Having gasterointestinal problems rather than functional abdomainal pain,

Patients who will not use three tablets

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
clinical Global Impression-severity(CGI-S)<br><br> To detect changing in severity of abdominal pain[At the end of 4 weeks];Wang-Baker Faces Pain Rating Score<br><br>To detect changing in abdominal pain rate[At the end of four weeks];Clinical Global Impression-Global Improvement (CGI-I)<br><br>For detecting the abdominal pain improvement.[At the end of treatment (week four)]

Secondary Outcome Measures

Name	Time	Method
Clinical Global Impression-Global Improvement (CGI-I)<br><br>For detecting the abdominal pain improvement[12 weeks after the end of treatment];clinical Global Impression-severity(CGI-S)<br><br> To detect changing in severity of abdominal pain[12 weeks after the end of treatment];Wang-Baker Faces Pain Rating Score<br><br>To detect changing in abdominal pain rate[12 weeks afte the e d of treatment]